SOTIO Expands ADC Pipeline and Synaffix collaboration to develop two novel bispecific candidates, SOT112 and SOT113

CAR-T Digest - August 2020

13 Mar 2025: SOTIO Expands ADC Pipeline and Synaffix collaboration to develop two novel bispecific candidates, SOT112 and SOT113

SOTIO is exercising its option under the agreement with Synaffix to obtain a license for developing two bispecific ADC programs
The bispecific candidates, SOT112 and SOT113, have the potential to be first-in-class or best-in-class treatments for solid tumors, with SOT113 specifically targeting prostate cancer
SOTIO will integrate Synaffix’s GlycoConnect, HydraSpace, and toxSYN platform technologies with its proprietary antibodies to develop ADC products
The collaboration reinforces SOTIO’s commitment to advancing innovative ADCs, leveraging bispecific ADCs for enhanced tumor-targeting precision
Synaffix will receive an upfront payment, milestone payments, and royalties, while SOTIO will handle research, development, manufacturing, and commercialization